RxDoctor Payments Data

Patrick McGill, MD

Family Medicine · Indianapolis, INNPI 1285665505

Payments from drug & device makers

$1,425in general payments, 2019–2025

Across 26 payments — averaging $54.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$966
  • Tempus AI, Inc$190
  • Lilly USA, LLC$67
  • Novo Nordisk$49
  • Pfizer$34
  • GSK$29
  • plus $92 from 5 others

What the payments were for

  • Consulting fees$87561%
  • Food & beverage$55039%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,425 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$22,885
Medicare patients
68
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$69,963
JanuviaSitagliptin Phosphate21$28,249
MounjaroTirzepatide18$25,988
Tresiba Flextouch U-200Insulin Degludec30$23,877
Soliqua 100-33Insulin Glargine/Lixisenatide17$14,312
EliquisApixaban12$13,317
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$7,224
GlyxambiEmpagliflozin/Linagliptin12$7,046
Breo ElliptaFluticasone/Vilanterol17$6,997
Combivent RespimatIpratropium/Albuterol Sulfate14$6,449
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$5,777
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen132$3,446
Humalog Kwikpen U-100Insulin Lispro15$3,122
LantusInsulin Glargine,hum.Rec.Anlog12$2,630
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$2,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$49$69,96354 claims
MerckJanuvia$13$28,24921 claims
Lilly USA, LLCMounjaro$67$25,98818 claims
PfizerEliquis$34$13,31712 claims
GSKBreo Ellipta$29$6,99717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →